Abstract
Colorectal cancer (CRC) liver metastasis (CLM) is the leading death cause of CRC patients, but there is no satisfied approach to treat CLM. Gut microbiota plays a pivotal role in CRC initiation and development. Targeting dysbiosis of the gut microbiota might open up new opportunities for CLM treatment. Here, we investigated the efficacy of sodium butyrate (NaB), a major product of gut microbial fermentation, in modulating gut microbiota in CLM mice. NaB supplement decreased mouse colon cancer CT26 cell liver metastasis in intrasplenic tumor injection model of BALB/c mice. Using 16S rRNA gene sequencing, we found altered microbiota composition in CLM mice, characterized by increases of Firmicutes and Proteobacteria. NaB beneficially changed dysbiosis in CLM mice. Functional analysis of the KEGG pathways showed that NaB changed pathways related to immune system diseases and primary immunodeficiency in CLM mice. In addition, NaB decreased T regulatory cells and increased natural killer T cells and T helper 17 cells, accordingly decreased IL-10 and increased IL-17 secretion in CLM mice liver. In conclusion, NaB beneficially modulated gut microbiota and improved host immune response in CLM mice. These findings demonstrate the therapeutic potential of NaB in CLM treatment.
Avoid common mistakes on your manuscript.
Liver metastasis is the leading cause of colorectal cancer (CRC)-related death. More than 50% of CRC patients develop colorectal liver metastasis (CLM) throughout their life. Though CRC incidence and mortality rates declined over the past decade, the 5-year survival rate for metastasized CRC patients is less than 10% (Nordlinger et al. 2013). Thus, there is a pressing need for new approaches to treating patients with CLM.
Gut microbiota regulates health and diseases. Increasing evidences suggest that gut microbiota plays a pivotal role in CRC initiation and development. The fecal microbiota from CRC patients promotes tumorigenesis in mice, indicating that altered microbiota promotes CRC formation (Wong et al. 2017). Gut microbiota-stimulated cathepsin K secretion promotes CRC metastasis (Li et al. 2019). Targeting dysbiosis of the gut microbiota might open up new opportunities for CLM treatment.
Diet influences the composition of the host gut microbiome. Gut microbiota ferments dietary fiber to produce short-chain fatty acids (SCFAs), such as butyrate. Sodium butyrate (NaB) administration beneficially changes gut microbiota composition and improves intestinal barrier in high-fat diet mice (Fang et al. 2019). NaB also influences the composition of gut microbiota and host colonic tumorigenesis (Zhang et al. 2018). CRC patients have significant reduction in the number of bacteria that produce SCFAs, including butyrate (Wu et al. 2016). Therefore, NaB may modulate the gut microbiota to attenuate the development of CRC. Here, we found that NaB rebalanced gut microbiota and modulated host immune response in CLM mice. Our findings provide insights into the therapeutic utility of NaB in CLM.
Five-week-old male BALB/c mice were randomly divided into four groups: PBS group (PBS), NaB group (NaB 350 mg/kg/day), CLM group (intrasplenic injection of 2 × 105 CT26 cells), and NaB + CLM group (NaB 350 mg/kg/day, intrasplenic injection of CT26 cells). Mice were sacrificed 10 days after inoculation. Fecal samples were collected for gut microbiota analysis. Liver and mesenteric lymph nodes (MLN) were collected for immune analysis (Supplementary material and methods). Results were presented as mean ± SEM. One-way ANOVA or t test was utilized for comparisons among groups. P < 0.05 was considered statistically significant.
Our results indicate that NaB had no effect on body weight gain and spleen tumor formation in mice (Fig. S1), but NaB dramatically repressed CLM (Fig. 1a). Clinic studies have demonstrated gut dysbiosis in CRC patients, such as higher level of pathogenic bacteria and lower level of SCFA-producing bacteria (Wirbel et al. 2019; Flemer et al. 2017). Gut dysbiosis has also been observed in mice model of colitis and colitis-associated CRC (Ibrahim et al. 2019), even in mice subcutaneously inoculated with CT26 cells (Wang et al. 2018). PCoA showed that the bacterial flora was changed in CLM mice (Fig. 1b). Taxonomic composition analysis revealed that severe dysbiosis in CLM mice with elevated proportion of Proteobacteria and Firmicutes, and decreased proportion of Bacteroidetes (Fig. 1c). The Firmicutes-to-Bacteroidetes ratio was significantly increased in CLM mice (Fig. 1d). Altered relative abundances of Bacteroidetes and Firmicutes are associated with the risk of CRC (Wirbel et al. 2019). NaB increased proportion of Bacteroidetes and decreased Firmicutes, accordingly reducing the Firmicutes-to-Bacteroidetes ratio in CLM mice (Fig. 1d).
In CLM mice (Fig. 1e), three organisms (Alistipes, Bacteroides, and Bacteroidaceae) related to CRC development in the phylum Bacteroidetes were increased compared with control group mice. Four organisms (streptococcus, Christensenellaceae, Clostridiales vadinBB60 group, and Clostridiales) were increased, and three organisms (Ruminococcus, Roseburia, and [Eubacterium] xylanophilum group) in the phylum Firmicutes were decreased compared with control mice. Three organisms (Helicobacter, Helicobacter ganmani, and Desulfovibrionaceae) in the phylum Proteobacteria were increased compared with control. Alistipes promotes CRC development via activation of IL-6/STAT3 signaling (Yang and Jobin 2017). Bacteroides overrepresented in CRC produces enterotoxin (Snezhkina et al. 2016). Clostridiales induces amino acid degradation in CRC (Wirbel et al. 2019). Helicobacter is involved in chronic inflammation (Abdulamir et al. 2011). Desulfovibrionaceae interferes with epithelial cell oxidative metabolism, which leads to cell damage (Balamurugan et al. 2008). Interestingly, the relative abundances of Alistipes, Bacteroides, Clostridiales, Helicobacter, and Desulfovibrionaceae were decreased in NaB-treated CLM mice. Thus, NaB could decrease the harmful pathogenic bacteria in CLM mice.
The energy source of colon cells mainly relies on SCFAs, especially butyrate. The gut microbiome of CRC promotes dysregulated glucose metabolism of SCFAs (Wang et al. 2019). The gut dysbiosis in mice with colitis and colitis-associated CRC is characterized by a decrease in the relative abundance of SCFA-producing bacteria, and the concentration of SCFAs accordingly decreased significantly in mice fecal samples (Ibrahim et al. 2019). High-fiber diet alters the microbiota composition and promotes the production of SCFAs in polyposis mice (Bishehsari et al. 2018). NaB significantly increased the relative abundance of Roseburia and [Eubacterium] xylanophilum group related to SCFA-producing in CLM mice. Thus, NaB could increase probiotic, such as SCFA-producing bacteria in CLM mice.
Furthermore, LEfSe showed that CLM resulted in marked metabolic profile changes (Fig. 2a, S2). Pathways related to signaling transduction, xenobiotics biodegradation, and metabolism were enriched in CLM mice. NaB changed functional pathways of immune system diseases in CLM mice. Gut microbiota plays an important role in shaping immune cell responses (Fessler et al. 2019). The liver is an essential immunological organ with a large number of immune cells. Compared with mice receiving PBS or NaB, CLM mice had decreased CD3+ and CD4+ T cells and increased CD8+ T and NK cells in the liver. NaB had no effect on CD3+, CD4+, CD8+ T, and NK cells, but markedly increased the frequency of natural killer T cells (NKT) cells in CLM mice liver (Fig. 2b, c, S3a). Bacteroides fragilis regulates the homeostasis of host invariant NKT cells (An et al. 2014). Pathogenic bacteria Streptococcus leads to a rapid reduction of NKT cell numbers (Chen et al. 2014). Study found that bile acid–controlled NKT cell accumulation mediates liver cancer inhibition (Ma et al. 2018). Thus, NaB suppresses CLM partially through inhibiting pathogenic bacteria-induced NKT cell downregulation in the liver.
T helper 17 (Th17)/T regulatory cells (Tregs) ratio and cytokine imbalance are important for CRC development (Amicarella et al. 2017). CRC patients have a higher proportion of Tregs that suppress tumor immune responses (Ling et al. 2007). CLM mice had increased CD4+CD25+CD127Low Tregs (Fig. 2d, S3b) and decreased CD4+IL-17A+ Th17 cells (Fig. 2e, S3c) both in the liver and MLN. NaB decreased the frequency of Tregs and increased Th17 cells in the liver but not in MLN. Accordingly, NaB decreased IL-10 protein while increasing IL-17 in CLM mice liver (Fig. 2f). These results demonstrated that the antitumor effect of NaB maybe related to regulating Tregs/Th17 cells and secretion of IL-10/IL-17 in the liver.
Our study revealed the dysbiosis of gut microbiota in CLM mice. Firmicutes to Bacteroidetes ratio significantly increased in CLM mice, but this ratio could be reduced by NaB. NaB decreased the relative abundance of pathogenic bacteria and increased the relative abundance of probiotic, such as SCFA-producing bacteria. Thus, NaB could decrease toxic bacterial products and increase beneficial bacterial metabolites. Moreover, the changes of gut microbiota by NaB increased NKT cells and Th17 cells and decreased Tregs, which lead to improved host anti-tumor immune response in CLM liver (Fig. 2g). This study highlights the therapeutic potential of NaB in CLM treatment.
Abbreviations
- NaB :
-
Sodium butyrate
- CRC :
-
Colorectal cancer
- CLM :
-
Colorectal liver metastasis
- SCFAs :
-
Short-chain fatty acids
- NK :
-
Natural killer
- Treg :
-
T regulatory
- Th17 :
-
T helper 17
References
Abdulamir AS, Hafidh RR, Abu BF. The association of Streptococcus bovis/gallolyticus with colorectal tumors: the nature and the underlying mechanisms of its etiological role. J Exp Clin Cancer Res. 2011;30:11–24.
Amicarella F, Muraro MG, Hirt C, Cremonesi E, Padovan E, Mele V, et al. Dual role of tumour-infiltrating T helper 17 cells in human colorectal cancer. Gut. 2017;66:692–704.
An D, Oh SF, Olszak T, Neves JF, Avci FY, Erturk-Hasdemir D, et al. Sphingolipids from a symbiotic microbe regulate homeostasis of host intestinal natural killer T cells. Cell. 2014;156:123–33.
Balamurugan R, Rajendiran E, George S, Samuel GV, Ramakrishna BS. Real-time polymerase chain reaction quantification of specific butyrate-producing bacteria, Desulfovibrio and Enterococcus faecalis in the feces of patients with colorectal cancer. J Gastroenterol Hepatol. 2008;23:1298–303.
Bishehsari F, Engen PA, Preite NZ, Tuncil YE, Naqib A, Shaikh M, et al. Dietary fiber treatment corrects the composition of gut microbiota, promotes SCFA production, and suppresses colon carcinogenesis. Genes (Basel). 2018;9:E102.
Chen J, Wei Y, He J, Cui G, Zhu Y, Lu C, et al. Natural killer T cells play a necessary role in modulating of immune-mediated liver injury by gut microbiota. Sci Rep. 2014;4:7259–70.
Fang W, Xue H, Chen X, Chen K, Ling W. Supplementation with sodium butyrate modulates the composition of the gut microbiota and ameliorates high-fat diet-induced obesity in mice. J Nutr. 2019;149:747–54.
Fessler J, Matson V, Gajewski TF. Exploring the emerging role of the microbiome in cancer immunotherapy. J Immunother Cancer. 2019;7:108–33.
Flemer B, Lynch DB, Brown JM, Jeffery IB, Ryan FJ, Claesson MJ, et al. Tumour-associated and non-tumour-associated microbiota in colorectal cancer. Gut. 2017;66:633–43.
Ibrahim A, Hugerth LW, Hases L, Saxena A, Seifert M, Thomas Q, et al. Colitis-induced colorectal cancer and intestinal epithelial estrogen receptor beta impact gut microbiota diversity. Int J Cancer. 2019;144:3086–98.
Li R, Zhou R, Wang H, Li W, Pan M, Yao X, et al. Gut microbiota-stimulated cathepsin K secretion mediates TLR4-dependent M2 macrophage polarization and promotes tumor metastasis in colorectal cancer. Cell Death Differ. 2019;26:2447–63.
Ling KL, Pratap SE, Bates GJ, Singh B, Mortensen NJ, George BD, et al. Increased frequency of regulatory T cells in peripheral blood and tumour infiltrating lymphocytes in colorectal cancer patients. Cancer Immun. 2007;7:7–14.
Ma C, Han M, Heinrich B, Fu Q, Zhang Q, Sandhu M, et al. Gut microbiome-mediated bile acid metabolism regulates liver cancer via NKT cells. Science. 2018;360:eaan5931.
Nordlinger B, Sorbye H, Glimelius B, Poston GJ, Schlag PM, Rougier P, et al. Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial. Lancet Oncol. 2013;14:1208–15.
Snezhkina AV, Krasnov GS, Lipatova AV, Sadritdinova AF, Kardymon OL, Fedorova MS, et al. The dysregulation of polyamine metabolism in colorectal cancer is associated with overexpression of c-Myc and C/EBPβ rather than enterotoxigenic Bacteroides fragilis infection. Oxidative Med Cell Longev. 2016;2016 United States:2353560.
Wang C, Yang S, Gao L, Wang L, Cao L. Carboxymethyl pachyman (CMP) reduces intestinal mucositis and regulates the intestinal microflora in 5-fluorouracil-treated CT26 tumour-bearing mice. Food Funct. 2018;9:2695–704.
Wang G, Yu Y, Wang YZ, Wang JJ, Guan R, Sun Y, et al. Role of SCFAs in gut microbiome and glycolysis for colorectal cancer therapy. J Cell Physiol. 2019;234:17023–49.
Wirbel J, Pyl PT, Kartal E, Zych K, Kashani A, Milanese A, et al. Meta-analysis of fecal metagenomes reveals global microbial signatures that are specific for colorectal cancer. Nat Med. 2019;25:679–89.
Wong SH, Zhao L, Zhang X, Nakatsu G, Han J, Xu W, et al. Gavage of fecal samples from patients with colorectal cancer promotes intestinal carcinogenesis in germ-free and conventional mice. Gastroenterology. 2017;153:1621–1633.e6.
Wu GD, Compher C, Chen EZ, Smith SA, Shah RD, Bittinger K, et al. Comparative metabolomics in vegans and omnivores reveal constraints on diet-dependent gut microbiota metabolite production. Gut. 2016;65:63–72.
Yang Y, Jobin C. Novel insights into microbiome in colitis and colorectal cancer. Curr Opin Gastroenterol. 2017;33:422–7.
Zhang Y, Kang C, Wang XL, Zhou M, Chen MT, Zhu XH, et al. Dietary factors modulate colonic tumorigenesis through the interaction of gut microbiota and host chloride channels. Mol Nutr Food Res 2018; 62.
Acknowledgments
We thank Dr. Guoqi Liu for gut microbiota assays.
Funding
This work was supported by the National Natural Science Foundation of China (No. 81272493, No. 81472213), the Health Commission of Zhejiang Province (No. 2019331258, No. 2019335600), the Natural Sciences Foundation of Zhejiang Province (No. LY17H220001), and the Science Technology Department of Zhejiang Province (No. GF20H220003, No. 2015C37112).
Author information
Authors and Affiliations
Contributions
G. W., Q. D., and H. D. participated in the design of the study. X. M., Z. Z., Z. X., M. F., and Y. H. performed the experiments. Q. D., G. W., X. M., Z. Z., Y. F., and H. D. contributed to data interpretation and wrote the manuscript. All authors read and approved the final manuscript.
Corresponding authors
Ethics declarations
Conflict of interest
The authors declare that they have no competing interests.
Additional information
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Electronic supplementary material
ESM 1
(DOC 26786 kb)
Rights and permissions
About this article
Cite this article
Ma, X., Zhou, Z., Zhang, X. et al. Sodium butyrate modulates gut microbiota and immune response in colorectal cancer liver metastatic mice. Cell Biol Toxicol 36, 509–515 (2020). https://doi.org/10.1007/s10565-020-09518-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10565-020-09518-4